{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nirmatrelvir
to a specific field?
There is one exact (name or code) match for nirmatrelvir
Status:
US Approved Rx
(2023)
Source:
NDA217188
(2023)
Source URL:
First approved in 2021
Source:
Nirmatrelvir by Pfizer Laboratories Div Pfizer Inc
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
US Approved Rx
(2023)
Source:
NDA217188
(2023)
Source URL:
First approved in 2021
Source:
Nirmatrelvir by Pfizer Laboratories Div Pfizer Inc
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
US Approved Rx
(2022)
Source:
NDA216340
(2022)
Source URL:
First approved in 2022
Source:
NDA216340
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
US Approved Rx
(2018)
Source:
NDA210861
(2018)
Source URL:
First approved in 2018
Source:
NDA210861
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Larotrectinib (previously known as ARRY-470 and LOXO-101) is a potent, oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases (TRKs). Larotrectinib is in phase II clinical trials for the treatment patients with solid tumors, non-Hodgkin lymphoma and for the pediatric patients with advanced solid or primary CNS tumors.
Status:
Investigational
Source:
INN:deunirmatrelvir [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
